Real-World Outcomes of Primary Versus Interval Debulking Surgery in a Multicenter Cohort of Advanced Ovarian Cancer Patients Treated with Bevacizumab.

Cancers (Basel) · 2026 · PMC12984216 · PMID 41827739

Europe PMC DOI

hedged sentence

0.0001

closest p · 0.0× alpha

0.0001

boldest claim

The sentences

highly significantp < 0.0001actually significant

The median OS for the PDS group was nearly double that of the IDS group, with a highly significant difference of 52.0 months versus 27.5 months (log-rank test, p < 0.0001). 4.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.